Aernoud Fiolet

106 Chapter 4 Table III. Baseline characteristic of participants randomized into the LoDoCo2 Trial (based upon non-final data, as of April 29, 2019) Characteristic Randomized patients (n = 5522) Age (years), mean (SD) 65.8 (± 8.6) Male, n (%) 4676 (84.7) Country Australia, n (%) 1904 (34.5) Netherlands, n (%) 3618 (65.5) Medical history Current Smoker, n (%) 654 (11.8) Hypertension, n (%) 2807 (50.8) Diabetes, n (%) 979 (17.7) Insulin Dependent, n (%) 279 (5.1) Renal Function Stage1,2, n (%) 5216 (94.5) Stage 3A, n (%)* 306 (5.5) Prior ACS, n (%) 4658 (84.4) Prior PCI, n (%) 4177 (75.6) Prior CABG, n (%) 710 (12.9) Atrial Fibrillation, n (%) 637 (11.5) Gout, n (%) 445 (8.1) Medication use at baseline Antiplatelet therapy, n (%) 5021 (90.9) Anti-coagulant (vitamin K antagonist ordirect oral anticoagulants), n (%) 668 (12.1) No anti-coagulant or antiplatelet, n (%) 26 (0.5) Statin, n (%) 5180 (93.8) Ezetimibe, n (%) 1068 (19.3) ACE Inhibitor or ARB, n (%) 3950 (71.5) Beta-Blocker, n (%) 3423 (62.0) Calcium Channel Blocker, n (%) 1228 (22.2) Participants were categorized at baseline into estimated glomerular filtration rate (eGFR) stages 1, 2, 3a (≥90, 60–89 or 45–59 ml/min/1.73 m 2 , respectively). * known GFR <50 is exclusion & GFR 50–60 or creatinine 120-150 mmol/l is considered as mild renal failure (stage 3a). Abbreviations: ACS, acute coronary syndrome; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention.